CEO Asaf Danziger (Novocure)
April 13, 2021 10:30 AM EDT
R&D

Tu­mor-treat­ing elec­tric fields show ear­ly promise in NSCLC — boost­ing both Novo­cure and its Chi­nese biotech part­ner

Amber Tong

More than a decade af­ter the FDA first ap­proved elec­tric fields as a treat­ment for glioblas­toma, Novo­cure said it’s seen a promis­ing sig­nal that they …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times